Susceptibility profile of clinical and environmental isolates of Cryptococcus neoformans and Cryptococcus gattii in Uberaba, Minas Gerais, Brazil

References

• Kwon-Chung KJ, Varma A. Do major species concepts support one, two or more species within Cryptococcus neoformans? FEMS Yeast Res 2006; 6: 574–587.
   PubMed Web of Science ®Google Scholar
• Mitchell TG, Perfect JR. Cryptococcosis in the era of AIDS – 100 years after the discovery of Cryptococcus neoformans. Clin Microbiol Rev 1995; 8: 515–548.
   PubMed Web of Science ®Google Scholar
• Stephen C, Lester S, Black W, Fyfe M, Raverty S. Multispecies outbreak of cryptococcosis on southern Vancouver Island, British Columbia. Can Vet J 2002; 43: 792–794.
   PubMed Web of Science ®Google Scholar
• Trilles L, Lazera Mdos S, Wanke B, et al. Regional pattern of the molecular types of Cryptococcus neoformans and Cryptococcus gattii in Brazil. Mem Inst Oswaldo Cruz 2008; 103: 455–462.
   PubMed Web of Science ®Google Scholar
• Yang YL, Cheng MF, Wang CW, et al. The distribution of species and susceptibility of amphotericin B and fluconazole of yeast pathogens isolated from sterile sites in Taiwan. Med Mycol 2010; 48: 328–334.
   PubMed Web of Science ®Google Scholar
• Arechavala AI, Ochiuzzi ME, Borgnia MD, Santiso GM. Fluconazole and amphotericin B susceptibility testing of Cryptococcus neoformans: results of minimal inhibitory concentrations against 265 isolates from HIV-positive patients before and after two or more months of antifungal therapy. Rev Iberoam Micol 2009; 26: 194–197.
   PubMed Web of Science ®Google Scholar
• Garcia-Martos P, Noval JF, Garcia-Tapia A, et al. Susceptibility to antifungal agents of Cryptococcus species of clinical interest. Med Clin (Barc) 2002; 119: 211–213 [in Spanish].
   PubMed Web of Science ®Google Scholar
• Pfaller MA, Messer SA, Boyken L, et al. Global trends in the antifungal susceptibility of Cryptococcus neoformans (1990 to 2004). J Clin Microbiol 2005; 43: 2163–2167.
   PubMed Web of Science ®Google Scholar
• Gomez-Lopez A, Zaragoza O, Dos Anjos Martins M, et al. In vitro susceptibility of Cryptococcus gattii clinical isolates. Clin Microbiol Infect 2008; 14: 727–730.
   PubMed Web of Science ®Google Scholar
• Bicanic T, Harrison T, Niepieklo A, Dyakopu N, Meintjes G. Symptomatic relapse of HIV-associated cryptococcal meningitis after initial fluconazole monotherapy: the role of fluconazole resistance and immune reconstitution. Clin Infect Dis 2006; 43: 1069–1073.
   PubMed Web of Science ®Google Scholar
• Sar B, Monchy D, Vann M, et al. Increasing in vitro resistance to fluconazole in Cryptococcus neoformans Cambodian isolates: April 2000 to March2002. J Antimicrob Chemother 2004; 54: 563–565.
   Web of Science ®Google Scholar
• De Bedout C, Ordonez N, Gomez BL, et al. In vitro antifungal susceptibility of clinical isolates of Cryptococcus neoformans var. neoformans and C. neoformans var. gattii. Rev Iberoam Micol 1999; 16: 36–39.
   PubMedGoogle Scholar
• Perkins A, Gomez-Lopez A, Mellado E, Rodriguez-Tudela JL, Cuenca-Estrella M. Rates of antifungal resistance among Spanish clinical isolates of Cryptococcus neoformans var. neoformans. J Antimicrob Chemother 2005; 56: 1144–1147.
   PubMed Web of Science ®Google Scholar
• Clinical and Laboratory Standards Institute. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts, approved standard, 3rd ed. Wayne, PA: Clinical and Laboratory Standards Institute; 2008.
   Google Scholar
• Costa AK, Sidrim JJ, Cordeiro RA, et al. Urban pigeons (Columba livia) as a potential source of pathogenic yeasts: a focus on antifungal susceptibility of Cryptococcus strains in Northeast Brazil. Mycopathologia 2010; 169: 207–213.
   PubMed Web of Science ®Google Scholar
• Heitman J, Kozel TR, Kwon-Chung KJ, Perfect JR, Casadevall A. Cryptococcus: From Human Pathogen to Model Yeast. Washinton, DC: ASM Press; 2010.
   Google Scholar
• Lockhart SR, Iqbal N, Bolden CB, et al. Epidemiologic cutoff values for triazole drugs in Cryptococcus gattii: correlation of molecular type and in vitro susceptibility. Diagn Microbiol Infect Dis 2012; 73: 144–148.
   PubMed Web of Science ®Google Scholar
• Turnidge J, Kahlmeter G, Kronvall G. Statistical characterisation of bacterial wild-type MIC value distributions and the determination of epidemiological cut-off values. Clin Microbiol Infect 2006; 12: 418–425.
   PubMed Web of Science ®Google Scholar
• Larsen RA, Bauer M, Pitisuttithum P, et al. Correlation of susceptibility of Cryptococcus neoformans to amphotericin B with clinical outcome. Antimicrob Agents Chemother 2005; 55: 5624–5630.
   Google Scholar
• Lopez-Jodra O, Torres-Rodriguez JM, Mendez-Vasquez R, et al. In vitro susceptibility of Cryptococcus neoformans isolates to five antifungal drugs using a colorimetric system and the reference microbroth method. J Antimicrob Chemother 2000; 45: 645–649.
   PubMed Web of Science ®Google Scholar
• Souza LK, Fernandes Ode F, Kobayashi CC, et al. Antifungal susceptibilities of clinical and environmental isolates of Cryptococcus neoformans in Goiania city, Goias, Brazil. Rev Inst Med Trop Sao Paulo 2005; 47: 253–256.
   PubMedGoogle Scholar
• Mora DJ, Pedrosa AL, Rodrigues V, et al. Genotype and mating type distribution within clinical Cryptococcus neoformans and Cryptococcus gattii isolates from patients with cryptococcal meningitis in Uberaba, Minas Gerais, Brazil. Med Mycol 2010; 48: 561–569.
   PubMed Web of Science ®Google Scholar
• Dannaoui E, Abdul M, Arpin M, et al. Results obtained with various antifungal susceptibility testing methods do not predict early clinical outcome in patients with cryptococcosis. Antimicrob Agents Chemother 2006; 50: 2464–2470.
   PubMed Web of Science ®Google Scholar
• Larsen RA, Bauer M, Brouwer AE, et al. In vitro-clinical correlations for amphotericin B susceptibility in AIDS-associated cryptococcal meningitis. Antimicrob Agents Chemother 2007; 51: 343–345.
   PubMed Web of Science ®Google Scholar
• Barchiesi F, Schimizzi AM, Caselli F, et al. Interactions between triazoles and amphotericin B against Cryptococcus neoformans. Antimicrob Agents Chemother 2000; 44: 2435–2441.
   PubMed Web of Science ®Google Scholar
• Souza LK, Souza Junior AH, Costa CR, et al. Molecular typing and antifungal susceptibility of clinical and environmental Cryptococcus neoformans species complex isolates in Goiania, Brazil. Mycoses 2010; 53: 62–67.
   PubMed Web of Science ®Google Scholar
• Liaw SJ, Wu HC, Hsueh PR. Microbiological characteristics of clinical isolates of Cryptococcus neoformans in Taiwan: serotypes, mating types, molecular types, virulence factors, and antifungal susceptibility. Clin Microbiol Infect 2010; 16: 696–703.
   PubMed Web of Science ®Google Scholar
• Brandt ME, Pfaller MA, Hajjeh RA, et al. Trends in antifungal drug susceptibility of Cryptococcus neoformans isolates in the United States: 1992 to 1994 and 1996 to1998. Antimicrob Agents Chemother 2001; 45: 3065–3069.
   Google Scholar
• Guinea J, Hagen F, Pelaez T, et al. Antifungal susceptibility, serotyping, and genotyping of clinical Cryptococcus neoformans isolates collected during 18 years in a single institution in Madrid, Spain. Med Mycol 2010; 48: 942–948.
   PubMed Web of Science ®Google Scholar
• Alves SH, Oliveira LT, Costa JM, et al. In vitro susceptibility to antifungal agents of clinical and environmental Cryptococcus neoformans isolated in Southern of Brazil. Rev Inst Med Trop Sao Paulo 2001; 43: 267–270.
   PubMedGoogle Scholar
• Andrade-Silva L, Ferreira-Paim K, Silva-Vergara ML, Pedrosa AL. Molecular characterization and evaluation of virulence factors of Cryptococcus laurentii and Cryptococcus neoformans strains isolated from external hospital áreas. Fungal Biol 2010; 114: 438–445.
   PubMed Web of Science ®Google Scholar
• Ferreira-Paim K, Andrade-Silva L, Mora DJ, et al. Genotyping of Cryptococcus neoformans isolated from captive birds in Uberaba, Minas Gerais, Brazil. Mycoses 2011; 54: 294–300.
   Google Scholar
• Litvintseva AP, Kestenbaum L, Vilgalys R, Mitchell TG. Comparative analysis of environmental and clinical populations of Cryptococcus neoformans. J Clin Microbiol 2005; 43: 556–564.
   PubMed Web of Science ®Google Scholar
• Orni-Wasserlauf R, Izkhakov E, Siegman-Igra Y, et al. Fluconazole-resistant Cryptococcus neoformans isolated from an immunocompetent patient without prior exposure to fluconazole. Clin Infect Dis 1999; 29: 1592–1593.
   PubMed Web of Science ®Google Scholar
• Aller AI, Claro R, Castro C, et al. Antifungal susceptibility of Cryptococcus neoformans isolates in HIV-infected patients to fluconazole, itraconazole and voriconazole in Spain: 1994–1996 and 1997–2005. Chemotherapy 2007; 53: 300–305.
   PubMed Web of Science ®Google Scholar
• Iqbal N, DeBess EE, Wohrle R, et al. Correlation of genotype and in vitro susceptibilities of Cryptococcus gattii strains from the Pacific Northwest of the United States. J Clin Microbiol 2010; 48: 539–544.
   PubMed Web of Science ®Google Scholar
• Kethireddy S, Andes D. CNS pharmacokinetics of antifungal agents. Expert Opin Drug Metab Toxicol 2007; 3: 573–581.
   PubMed Web of Science ®Google Scholar
• Mondon P, Petter R, Amalfitano G, et al. Heteroresistance to fluconazole and voriconazole in Cryptococcus neoformans. Antimicrob Agents Chemother 1999; 43: 1856–1861.
   PubMed Web of Science ®Google Scholar
• Perfect JR, Savani DV, Durack DT. Comparison of itraconazole and fluconazole in treatment of cryptococcal meningitis and candida pyelonephritis in rabbits. Antimicrob Agents Chemother 1986; 29: 579–583.
   PubMed Web of Science ®Google Scholar
• Pfaller MA, Castanheira M, Diekema DJ, Messer SA, Jones RN. Wild-type MIC distributions and epidemiologic cutoff values for fluconazole, posaconazole, and voriconazole when testing Cryptococcus neoformans as determined by the CLSI broth microdilution method. Diagn Microbiol Infect Dis 2011; 71: 252–259.
   Google Scholar
• Pfaller MA, Castanheira M, Messer SA, Moet GJ, Jones RN. Echinocandin and triazole antifungal susceptibility profiles for Candida spp., Cryptococcus neoformans, and Aspergillus fumigatus: application of new CLSI clinical breakpoints and epidemiologic cutoff values to characterize resistance in the SENTRY Antimicrobial Surveillance Program (2009). Diagn Microbiol Infect Dis 2011; 69: 45–50.
   PubMed Web of Science ®Google Scholar
• Trilles L, Meyer W, Wanke B, Guarro J, Lazera M. Correlation of antifungal susceptibility and molecular type within the Cryptococcus neoformans/C. gattii species complex. Med Mycol 2012; 50: 328–332.
   Google Scholar
• Fernandes FLO, Passos XS, Souza LK, et al. In vitro susceptibility characteristics of Cryptococcus neoformans varieties from AIDS patients in Goiania, Brazil. Mem Inst Oswaldo Cruz 2003; 98: 839–841.
   PubMed Web of Science ®Google Scholar
• Silva PR, Rabelo RA, Terra AP, Teixeira DN. Susceptibility to antifungal agents among Cryptococcus neoformans varieties isolated from patients at a university hospital. Rev Soc Bras Med Trop 2008; 41: 158–162 [in Spanish].
   PubMed Web of Science ®Google Scholar